Top 2% Biotech Flirts With Profit-Taking Zone On $145 Million Deal

By Investor's Business Daily   |   2 years ago
Top 2% Biotech Flirts With Profit-Taking Zone On $145 Million Deal

Biotech company ARS Pharmaceuticals saw a surge in shares after partnering with ALK-Abello to market its nasal spray Neffy for allergic reactions globally. The deal includes a $145 million upfront payment and potential milestones and royalties, targeting a large epinephrine market.

Read More

Did you find this insightful?